<DOC>
	<DOCNO>NCT01864512</DOCNO>
	<brief_summary>This project undertake Qilu Hospital Shandong University well-known hospital China . In order report alteration Different Immune Parameters ITP Patients Receiving Eltrombopag Treatment .</brief_summary>
	<brief_title>Alteration Different Immune Parameters Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment</brief_title>
	<detailed_description>The primary objective study determine efficacy oral eltrombopag thrombopoietic agent treat previously treat chronic Chinese ITP patient investigate alteration Different Immune Parameters eltrombopag therapy . Approximately 30 eligible subject primary ITP respond relapse previous treatment ITP select . The initial dose eltrombopag administration 25 mg orally daily . During 6 week follow-up , dose investigational product adjust accord weekly subject platelet count , battery immune parameter monitor end week . Additionally , efficacy oral eltrombopag ITP assess 6 week administration .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Subject ≥18 year old . 2 . Diagnosed ITP least 12 month prior screen , platelet count &lt; 30 X109/L Day 1 ( within 48 hour prior dose Day 1 ) . 3 . Patients response relapse splenectomy . Or patient splenectomised either respond one prior therapy ( except splenectomy ) , relapse prior therapy . 4 . Previous therapy ITP include rescue must complete least 2 week prior randomization , TPOR agonists , romiplostim recombinant human thrombopoietin ( rhTPO ) , must complete 30 day enrollment . 5 . Subjects treat maintenance immunosuppressive therapy must receive dose stable least 1 month . 6 . No preexist cardiac disease within last 3 month . No arrhythmia know increase risk thrombolic event ( e.g . atrial fibrillation ) , patient Corrected QT interval ( QTc ) &gt; 450msec QTc &gt; 480 patient Bundle Branch Block . 7 . No history clot disorder , ITP . 8 . A complete blood count ( CBC ) , within reference range , follow exception : Platelets &lt; 30×109/L Day 1 ( within 48hours Day 1 ) require inclusion , Hemoglobin : female males 10.0 g/dl eligible inclusion , Absolute neutrophil count ( ANC ) ≥1500/µL ( 1.5×109/L ) require inclusion 9 . Blood chemistry test result exceed normal 20 % . Total albumin must lower limit normal ( LLN ) 10 % . 10 . Subject nonchildbearing potential childbearing potential use acceptable method contraception two week prior administration study medication , throughout study , 28 day completion premature discontinuation study . 1 . Patients prior history arterial venous thrombosis , AND ≥ two follow risk factor : hormone replacement therapy , systemic contraception ( contain estrogen ) , smoke , diabetes , hypercholesterolemia , medication hypertension , cancer , hereditary thrombophilic disorder ( e.g. , Factor V Leiden , ATIII deficiency , antiphospholipid syndrome , etc ) . 2 . Any clinically relevant abnormality , ITP , opinion investigator make subject unsuitable participation study . 3 . Female subject nurse pregnant screen predose Day 1 . 4 . History alcohol/drug abuse dependence within 12 month study . 5 . Treatment investigational drug within 30 day five halflives ( whichever longer ) precede first dose study medication . 6 . Subjects previously receive eltrombopag therapy . 7 . Subject consume aspirin , aspirincontaining compound , salicylate , anticoagulant , quinine nonsteroidal antiinflammatories ( NSAIDs ) &gt; 3 consecutive day within 2 week study start end study . 8 . Consumption herbal dietary supplement , exclude vitamin mineral supplement , within 1 week study start . 9 . History platelet aggregation prevents reliable measurement platelet count . 10 . An abnormality bone marrow examination result , ITP , identify screen examination , opinion investigator make subject unsuitable participation study . 11 . Any laboratory clinical evidence HIV infection ; clinical history hepatitis C infection ; chronic hepatitis B infection ; evidence active hepatitis time subject screening . Laboratory test screening show evidence hepatitis C infection hepatitis B infection . 12 . Patients expect require rescue Day 1 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Immune Thrombocytopenia</keyword>
	<keyword>eltrombopag</keyword>
	<keyword>immune regulation</keyword>
</DOC>